Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease

Meghan E. Sise, Thomas McQuaid, Paul Martin

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Sofosbuvir (SOF), a nucleotide inhibitor of the hepatitis C virus (HCV) polymerase, is a component of several all-oral HCV therapies. GS-331007, SOF’s predominant metabolite, is renally eliminated and accumulates 5- to 20-fold in patients with advanced chronic kidney disease (CKD) or undergoing hemodialysis (HD), respectively. Preclinical data did not determine whether these exposures represented a risk for toxicity. Therefore subjects with advanced CKD were not included in registrational studies and SOF was not initially approved for use in advanced CKD. Nevertheless, after initial licensing, off-label use of SOF at full or reduced doses was reported in patients with kidney disease. Two clinical trials of SOF-containing therapies were conducted in patients with end-stage kidney disease, demonstrating safety and efficacy. These led to expanded US Food and Drug Administration approval in 2019 for the use of SOF-containing regimens in patients with advanced CKD, including dialysis dependence. Even so, given the availability of protease inhibitor–containing direct-acting antiviral regimens, there was a reluctance by some practitioners to use SOF-containing regimens in moderate to severe kidney disease. Here we review the existing data on SOF’s pharmacokinetics, toxicology, efficacy and safety in patients with kidney disease. Data from both clinical trials and real-world practice settings indicate that in patients with moderate to severe kidney disease, full-dose SOF-based regimens have high rates of efficacy and acceptable safety and tolerability profiles, without increased risk for cardiac adverse events or clinically meaningful changes in kidney function. SOF-based regimens are safe and effective in patients who have moderate to severe kidney disease, including those undergoing HD.

Original languageEnglish
Pages (from-to)2327-2334
Number of pages8
JournalNephrology Dialysis Transplantation
Issue number12
StatePublished - 1 Dec 2022
Externally publishedYes


  • chronic hepatitis C infection
  • direct-acting antiviral
  • end-stage kidney disease
  • severe renal impairment


Dive into the research topics of 'Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease'. Together they form a unique fingerprint.

Cite this